{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-23-000160","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.647227+00:00","generated_at":"2026-06-08T07:25:59.511030+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Humacyte Q3 net loss $26M; positive V005 trauma trial results, BLA filing planned this quarter","bullets":["Cash and equivalents $100M; funding from Oberland up to $160M, $40M received.","Net loss $26.0M Q3 2023 vs $25.3M Q3 2022; R&D expenses $18.6M.","V005 Phase 2/3 trial: 30-day patency 90.2%, amputation rate 9.8%, infection rate 2.0% (vs historic synthetic benchmarks).","BLA for HAV in vascular trauma planned for FDA filing in Q4 2023.","Ukraine humanitarian program: 30-day patency 95%, limb salvage and survival 100%, zero infections."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-23-000160","json":"https://secwatch.observer/filing/0001818382-23-000160.json","markdown":"https://secwatch.observer/filing/0001818382-23-000160.md","text":"https://secwatch.observer/filing/0001818382-23-000160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000160/0001818382-23-000160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000160/huma-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:25:59.511030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ccf825e8b4854911ca6e31436031c530caa0445","claim":"Humacyte, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000160/0001818382-23-000160-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}